Search This Blog

Translate

Pages

728x90

بحث / search

mob

468x60

Saturday, December 23, 2023

 


Submission of updated batch records

Annual report (with one batch with three months

accelerated and one batch on long-term stability data)

2. Dissolution documentation Case B testing

3. In vivo bioequivalence None

documentation

Filing Documentation

i. Changes being affected supplement

ii. Annual report (with long-term stability data)

SUPAC Guidelines and Platform Technology 35

D. Changes in Manufacture

This section includes changes in both equipment as well as process.

I. Equipment

a. Level 1

Definition: This consists of (1) change from non-mechanical or non-automated

equipment to mechanical or automated equipment to move ingredients; and (2) Change

to alternative equipment of the same operating and design principles of the same

different capacity.

Test documentation (Table 3.12)

Table 3.12: Test documentation required as per SUPAC guidelines level 1

Sr. no. Type of test documentation Content

1. Chemistry documentation Application/compendial release requirements

Stability (one batch on long-term stability studies)

Submission of batch records

2. Dissolution documentation None beyond application/compendial requirements

3. In vivo bioequivalence None

documentation

Filing Documentation

Annual report (long-term stability data)

b. Level 2

Definition: It consists of change to a different: (1) Design (2) Operating system

Test documentation (Table 3.13)

Table 3.13: Test documentation required as per SUPAC guidelines level 2

Sr. no. Type of test documentation Content

1. Chemistry documentation Application/compendial release requirements

Stability (one batch on long-term stability studies),

Submission of batch records

A significant body of information available

One batch with three months accelerated stability data

reported in the supplement; one batch on long-term

stability data reported in an annual report.

A significant body of information not available

Up to three batches with three months accelerated

stability data reported in the supplement; one batch

on long-term stability data reported in an annual

report.

2. Dissolution documentation Case C: Dissolution profile.

3. In vivo bioequivalence None

documentation

36 Industrial Pharmacy II

Filing Documentation

i. Prior approval supplement with justification for change;

ii. Annual report (long-term stability data).

II. Process

No comments:

Post a Comment